Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin

Thrombosis and Haemostasis

Volumn 91, Issue 5, 2004, Pages 935-940

  Hoke, Matthias ^a   Kyrle, Paul A ^a,b   Philipp, Karl ^c   Pabinger, Ingrid ^a   Kaider, Alexandra ^a   Schönauer, Verena ^a   Quehenberger, Peter ^a   Eichinger, Sabine ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c DANUBE HOSPITAL   (Austria)

Author keywords

APC resistance; D Dimer; Low molecular weight heparin; Pregnancy

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ABORTION; ADULT; ANAMNESIS; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECLAMPSIA; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MEASUREMENT; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; SECOND TRIMESTER PREGNANCY; SOLUTIO PLACENTAE; STILLBIRTH; THIRD TRIMESTER PREGNANCY; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 2442460811     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-11-0719     Document Type: Article

References (22)

1. Koonin LM, MacKay AP, Berg CJ, et al. Pregnancy-related mortality surveillance - United States, 1987-1990. MMWR CDC Surveill Summ 1997; 46: 17-36.
2. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
3. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
4. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-8.
5. Hunt BJ, Doughty HA, Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
6. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.
7. Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12: 141-54.
8. de Moerloose P, Amiral J, Vissac AM, et al. Longitudinal study on activated factors XII and VII levels during normal pregnancy. Br J Haematol 1998; 100: 40-4.
9. Eichinger S, Weltermann A, Philipp K et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999; 82: 1232-6.
10. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-73.
11. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
12. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
13. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70.
14. Crowder MJ, Hand DJ. Analysis of Repeated Measures. Chapman and Hall, London; 1990.
15. Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-82.
16. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
17. Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-2.
18. Mathonnet F, de Mazancourt P, Bastenaire B et al. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996; 92: 244-6.
19. Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177: 162-9.
20. Cumming AM, Tait RC, Fildes S, et al. Diagnosis of APC Resistance during pregnancy. Br J Haematol 1996; 92: 1026-9.
21. Benedetto C, Marozio L, Tavella AM, et al. Response to activated protein C decreases throughout pregnancy. Acta Obstet Gynecol Scand 2002; 81: 1028-32.
22. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med 2000; 343: 1439-44.